This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Dementia in Alzheimer disease with late onset만기발병 알츠하이머병에서의 치매

Contents and key points
ItemDetails
A. Classification codesICD-10: F00.1 (G30.1†) — mental and behavioral axis code. Paired code: G30.1 (neurological axis) | Special Copayment Reduction: V810 (severe intractable disease, 5 years)
B. SynonymsAlzheimer disease type 1, primary degenerative dementia of the Alzheimer type (senile onset), senile dementia of the Alzheimer type, senile dementia of Alzheimer type (SDAT)
C. Adult onsetYes — onset at age 65 or older by definition; the most common cause of dementia in old age.
1. HistoryHistory of senile dementia; continuity with Alzheimer disease established in 1976; NINCDS-ADRDA criteria in 1984; NIA-AA revisions in 2011 and 2018.
2. CausesAPOE ε4; advanced age; polygenic risk; vascular risk factors; education level; combination of modifiable risk factors.
3. GeneticsAPOE ε4 as the main risk factor; genes found by GWAS (BIN1, CLU, CR1, TREM2, etc.); polygenic risk score.
4. General epidemiologyAbout 95% of all Alzheimer; prevalence at age 65 and older about 5–7%; age 85 and older about 20–40%; dementia prevalence at age 65 and older in Korea about 10%.
5. PathophysiologyAmyloid hypothesis; tau pathology; neuroinflammation; mitochondrial dysfunction; vascular component; cognitive reserve.
6. SymptomsPredominant short-term episodic memory impairment; gradual multidomain cognitive decline; behavioral and psychological symptoms (BPSD); decline in daily functioning.
7. SignsNeuropsychological testing (MMSE, MoCA, CDR); brain MRI (medial temporal lobe atrophy); amyloid and tau PET; cerebrospinal fluid/plasma biomarkers.
8. ScreeningCognitive function assessment of high-risk groups aged 65 and older; Korean dementia early screening program; increasing use of blood biomarkers such as plasma p-tau217.
9. DiagnosisNIA-AA 2018 A/T/N framework; differential diagnosis (vascular, LBD, FTD); basic blood and imaging tests.
10. TreatmentCholinesterase inhibitors; memantine; lecanemab and donanemab (early AD); management of behavioral symptoms; caregiver support.
11. PrognosisMedian survival after diagnosis about 8–12 years; main causes of death: aspiration pneumonia, infection; prevention of complications is important for life expectancy.
12. PreventionManagement of 12 modifiable risk factors; multidomain interventions such as FINGER; moderate-intensity aerobic exercise; social participation.
13. ReferencesScheltens P et al. Lancet 2021 and 9 other references

1. History

In ICD-10, F00.1 is the mental and behavioral axis code describing dementia due to Alzheimer disease with onset at age 65 or older, paired in a dual coding (dagger-asterisk) system with the neurological axis code G30.1 (Alzheimer disease with late onset). F00.1 is the code describing the mental and behavioral aspect of the dementia syndrome due to the underlying neurological disease, late-onset Alzheimer disease (G30.1†). The two codes code the same clinical entity from different perspectives (psychiatric axis vs. neurological axis); the F code emphasizes dementia symptoms, decline in daily functioning, and behavioral changes, while the G code emphasizes the neuropathology and stage of progression of Alzheimer disease itself.

Historically, memory and cognitive impairment arising at age 65 or older was long regarded as part of "normal aging" or as a separate "senile dementia," and was considered a different disease from the presenile (under 65) Alzheimer disease described by Alois Alzheimer. In 1968, Martin Roth and colleagues in the UK systematically reported that neurofibrillary tangles and amyloid plaques are also observed in the brains of patients with senile dementia. In 1976, Robert Katzman, in an influential paper, argued that senile dementia and Alzheimer disease are the same disease, emphasizing that this disease is not a simple aging phenomenon but an abnormal pathological process.

Subsequently, the NINCDS-ADRDA clinical diagnostic criteria were established in 1984 and became the standard for clinical research. In 2011, the NIA-AA published new criteria dividing the disease into three stages: preclinical, mild cognitive impairment (MCI due to AD), and Alzheimer dementia. In 2018 the biomarker-based A/T/N framework was proposed, making it possible to define Alzheimer pathology biologically even at the preclinical stage without clinical symptoms. With the FDA approval of lecanemab in 2023 and donanemab in 2024, disease-modifying treatment of early Alzheimer dementia began to be introduced in clinical practice.


2. Causes

Late-onset Alzheimer disease (age 65 and older, LOAD: late-onset AD) accounts for about 95% of all Alzheimer disease and arises from the combined action of polygenic risk and environmental factors rather than a single-gene variant.

Advanced age

Age is the strongest risk factor for Alzheimer dementia. Prevalence rises sharply from about 1–2% at ages 65–69 to about 20–40% at age 80 and older. Age-related decline in amyloid clearance mechanisms, mitochondrial functional decline, increased oxidative stress, decreased autophagy, and vascular aging contribute in combination.

APOE ε4

APOE ε4 is the strongest genetic risk factor for LOAD, associated with about a 3–4-fold increase in risk in heterozygotes and about an 8–15-fold increase in homozygotes, and with onset about 10 years earlier. APOE ε4 impairs amyloid plaque clearance and also affects cerebral vascular function and lipid metabolism.

Vascular risk factors

Hypertension (especially in midlife), diabetes, obesity, dyslipidemia, smoking, and atrial fibrillation are independent risk factors for Alzheimer disease. Vascular risk factors worsen Alzheimer pathology through cerebral small vessel disease (CSVD), and mixed type (Alzheimer + vascular pathology) is more common in late-life dementia than pure Alzheimer pathology.

Modifiable risk factors

These include low education level, hearing loss, depression, physical inactivity, social isolation, traumatic brain injury, and air pollution. The 2020 Lancet Commission on dementia estimated that these risk factors account for about 40% of all dementia.


3. Genetics

The genetics of late-onset Alzheimer disease has a polygenic structure in which many common variants act in combination, rather than a single-gene variant.

APOE gene

The APOE gene on chromosome 19 has three alleles: ε2, ε3, and ε4. ε4 increases LOAD risk through several mechanisms, including impaired amyloid plaque clearance, reduced LRP1-mediated Aβ transport, and reduced vascular function. In contrast, ε2 shows a protective effect (LOAD risk about 50% lower in ε2 carriers).

Risk genes found by GWAS

Large-scale genome-wide association studies (GWAS) of Alzheimer disease have identified about 85 or more risk loci to date. Major genes include BIN1 (synaptic vesicle trafficking), CLU (clusterin, Aβ clearance), CR1 (complement receptor, neuroinflammation), PICALM (synaptic vesicle endocytosis), TREM2 (microglial function, Aβ clearance), ABCA7, MS4A6A, and CD33. These genes contribute to Alzheimer pathology through various pathways, including immune/inflammatory response, lipid metabolism, synaptic function, and intracellular signaling.

Polygenic risk score

The polygenic risk score (PRS), which quantifies the combined effect of individual risk alleles, is used to predict the risk of developing LOAD and provides additional predictive power independent of APOE genotype.


4. General epidemiology

Worldwide, Alzheimer dementia patients were estimated at about 55 million as of 2024, of whom about 95% have late onset at age 65 and older. Prevalence is about 1–2% at ages 65–69, about 6–8% at ages 75–79, about 12–16% at ages 80–84, and about 25–40% at age 85 and older, increasing exponentially with age. Worldwide, a new dementia patient arises every 3 seconds, and the number is projected to rise to about 150 million by 2050.

By sex, women show a higher prevalence than men, which is known to be due to hormonal and genetic factors in addition to women's longer life expectancy. It has been reported that the APOE ε4 allele has a greater effect of increasing LOAD risk in women.

In Korea, according to the 2023 dementia epidemiology survey of the Central Dementia Center, the prevalence of dementia at age 65 and older is about 10.4% (about 920,000 people), of which Alzheimer dementia accounts for about 75%. Korea's population aging is among the fastest in the world, and dementia patients are projected to reach about 3 million by 2050. A national dementia early screening program centered on Dementia Relief Centers and a Dementia Relief Hospital system have been established.


5. Pathophysiology

The pathophysiology of late-onset Alzheimer disease shares its basic pathology (amyloid and tau hypotheses) with early onset, with the added complex feature of additional contributions from aging and a vascular component.

Imbalance between amyloid production and clearance

In LOAD, reduced Aβ clearance mechanisms play a more important role than Aβ production itself. Age-related decline in cerebrospinal fluid circulation and glymphatic system function, blood-brain barrier damage, reduced LRP1-mediated transport due to ApoE ε4, and reduced Aβ phagocytic capacity of microglia promote Aβ accumulation.

Tau pathology and spread within the brain

Hyperphosphorylation and aggregation of tau protein begin in the entorhinal cortex and spread to the hippocampus, association cortex, and prefrontal cortex in that order (Braak stages). This spreading process is explained by a prion-like mechanism, in which pathogenic tau seeds move to adjacent cells and induce hyperphosphorylation of normal tau.

Neuroinflammation

Because GWAS risk genes such as TREM2 and CR1 are related to microglial function, neuroinflammation is regarded as playing an independent and important role in pathogenesis. Reduced Aβ clearance by microglia and chronic neuroinflammation due to overactivation alternate and deepen the pathology.

Role of cognitive reserve and aging

Cognitive reserve is the adaptive capacity of the brain accumulated through high education level, complex occupational history, and active social activity, and explains the phenomenon in which clinical symptom onset is delayed or attenuated despite the same pathological burden. Aging itself creates an environment vulnerable to Alzheimer pathology through reduced brain volume, white matter degeneration, reduced vascular function, and mitochondrial functional decline.


6. Symptoms

The clinical symptoms of late-onset Alzheimer dementia (F00.1) mostly begin centered on episodic memory impairment, and compared with early onset (F00.0), they often show a typical phenotype in which memory symptoms are more prominent.

Early symptom: episodic memory impairment

Repeatedly forgetting recent events, conversations, and appointments is the earliest symptom. Family members often notice before the patient does, and behaviors such as repeating the same words or being unable to find important objects appear. Difficulty finding words (anomia) due to semantic memory (language knowledge) impairment may also occur from early on.

Symptoms of moderate progression

Language impairment (reduced fluency, difficulty understanding), visuospatial processing abnormalities (getting lost, difficulty driving, inability to draw complex figures), executive dysfunction (household accounts calculation, managing medication, using electronic devices), and apraxia (errors in sequential activities such as dressing and cooking) appear. Instrumental ADL (using the telephone, mobility, shopping, financial management) gradually declines.

Behavioral and psychological symptoms (BPSD)

Apathy is the most common non-cognitive symptom, and depression, anxiety, sleep disturbance, appetite changes, agitation, aggression, wandering, delusions (such as delusions of theft), and hallucinations may appear. BPSD greatly increases caregiver burden and is a major cause of institutionalization.

Late symptoms

Complete dependence in basic ADL (washing, eating, mobility), loss of speech (mutism), gait disturbance, dysphagia, urinary and fecal incontinence, and increased vulnerability to infections (aspiration pneumonia, urinary tract infection) appear.


7. Signs

The objective tests used to diagnose late-onset Alzheimer dementia are the same as for early onset, but in elderly patients it is important to apply normative scores that take into account education level and social and cultural background.

For neuropsychological testing, the MMSE, MoCA, CDR (Clinical Dementia Rating), K-MMSE-2, and CERAD-K (Consortium to Establish a Registry for Alzheimer's Disease, Korean version) are used as standards in Korea. The CDR assesses 6 domains — memory, orientation, judgment and problem solving, community affairs, home and hobbies, and personal care — and classifies as CDR 0.5 (questionable dementia), 1 (mild), 2 (moderate), and 3 (severe).

On brain MRI, atrophy of the medial temporal lobe (hippocampus, entorhinal cortex) is the characteristic finding of LOAD. In late onset, diffuse cerebral cortical atrophy is often accompanied by ventricular enlargement and white matter hyperintensities (WMH). Plasma p-tau217 has recently shown the highest diagnostic accuracy among Alzheimer biomarkers (AUC 0.96 or higher), and its clinical use is expanding.


8. Screening

In Korea, a national dementia early screening program is carried out for early detection of dementia. For those aged 60 and older, Dementia Relief Centers carry out screening tests (MMSE-DS or CIST), diagnostic tests (neuropsychological testing, blood tests, MRI), and differential tests in stages.

Recently, as the diagnostic accuracy of plasma biomarkers (plasma p-tau217, p-tau181, Aβ42/Aβ40, GFAP) has improved, it is becoming possible to predict Alzheimer pathology from a blood test alone, without expensive PET imaging or cerebrospinal fluid testing. This is increasing the practical feasibility of large-scale screening programs.

APOE ε4 genotype testing can be used to predict Alzheimer risk, but it should be performed together with specialized genetic counseling, considering the psychological impact of test results and the possibility of discrimination.


9. Diagnosis

Diagnosis of late-onset Alzheimer dementia is made by integrating the NIA-AA 2018 A/T/N biomarker framework with clinical criteria. The keys to clinical diagnosis are ① cognitive decline (confirmed by neuropsychological testing), ② decline in daily functioning (CDR ≥1), and ③ exclusion of other causes.

The basic evaluation includes comprehensive history taking (time of onset, pattern of progression, family history), physical and neurological examination (parkinsonian symptoms, pyramidal signs, cranial nerve abnormalities), neuropsychological testing, brain MRI (to exclude structural and vascular lesions), and blood tests (thyroid function, vitamin B12, folate, complete blood count, renal and liver function, fasting blood glucose, syphilis serology, etc.).

Biomarker-confirmed diagnosis: cerebrospinal fluid Aβ42, p-tau, t-tau, or amyloid PET (Pittsburgh compound B, florbetapir, flutemetamol, florbetaben). As of 2025, plasma p-tau217 is in the major validation stage for clinical use, and guidance on its use as an adjunct diagnostic tool is being prepared in some guidelines.

In differential diagnosis, exclude dementia with Lewy bodies (REM sleep behavior disorder, parkinsonian symptoms, fluctuating cognition), vascular dementia (stepwise progression, focal neurological signs, history of stroke), frontotemporal dementia (predominant personality change and disinhibition, reduced language expression), normal pressure hydrocephalus (the triad of gait disturbance, urinary incontinence, and cognitive impairment), and reversible causes (hypothyroidism, vitamin B12 deficiency, depression, etc.).


10. Treatment

Treatment of late-onset Alzheimer dementia follows the same pharmacological principles as early onset, but an individualized approach is needed that takes into account polypharmacy, reduced renal and liver function, fall risk, and comorbid cardiovascular disease in elderly patients.

Cholinesterase inhibitors: donepezil (5→10 mg/day), rivastigmine (oral or patch), and galantamine (extended-release) are used in mild-to-moderate dementia. Donepezil 23 mg can also be used in moderate-to-severe dementia. Memantine: in moderate-to-severe dementia, alone or in combination with a cholinesterase inhibitor. Anti-amyloid treatment: lecanemab and donanemab are indicated for amyloid-positive patients at the mild cognitive impairment or mild dementia stage, and regular MRI is required for ARIA monitoring. Because the risk of ARIA may be increased in elderly patients, carefully evaluate whether the eligibility criteria are met.

Management of behavioral and psychological symptoms (BPSD): Non-pharmacological approaches (environmental modification, structured daily routine, reminiscence therapy, music therapy) are implemented first. Drug treatment is used only when symptoms are severe and non-pharmacological treatment is insufficient, and when using antipsychotics (low-dose quetiapine, risperidone), inform patients and caregivers of the increased risk of stroke and death (boxed warning). Caregiver education and support services are essential, and cognitive rehabilitation services of local Dementia Relief Centers are used.


11. Prognosis

Median survival after diagnosis of late-onset Alzheimer dementia is about 8–12 years, but varies widely with age of onset, APOE genotype, and comorbid conditions. When diagnosed at age 80 or older, life expectancy is already short, so survival after diagnosis tends to be shorter. The most common cause of death is aspiration pneumonia, with reduced swallowing function and immunosuppression as the main mechanisms. Urinary tract infection, pressure ulcers, and fractures from falls are also major complications and causes of death.

As dementia severity increases, the burden on family and informal caregivers grows, and the resulting caregiver depression and health problems are also an important public health issue. To maintain the quality of life of dementia patients, it is recommended to discuss advance care planning, access to palliative care, and decisions about death with dignity in advance.


12. Prevention

Management of modifiable risk factors is key to preventing late-onset Alzheimer disease. The 2024 update of the Lancet Commission on dementia added visual impairment, high LDL cholesterol, and physical inactivity to the 9 existing risk factors and reported that 14 risk factors account for 45% of all dementia.

Management of blood pressure, blood glucose, and weight in midlife (ages 45–65) reduces the risk of Alzheimer disease in old age the most. Moderate-intensity aerobic exercise (150 minutes per week) helps maintain hippocampal volume, increase BDNF, and promote amyloid clearance. Cognitively stimulating activities such as music, reading, and foreign language learning improve cognitive reserve. A Mediterranean-style diet (MIND diet), smoking cessation, moderate alcohol consumption, and increased social participation are also recommended. Use of hearing aids and correction of vision by eyeglasses or cataract surgery have also recently been included in prevention strategies.


13. References

  1. Scheltens P, De Strooper B, Kivipelto M, et al. Alzheimer's disease. Lancet. 2021;397(10284):1577-1590. DOI: 10.1016/S0140-6736(20)32205-4. PMID: 33667450.
  2. Jack CR Jr, Bennett DA, Blennow K, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018;14(4):535-562. DOI: 10.1016/j.jalz.2018.02.018. PMID: 29653606.
  3. van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in Early Alzheimer's Disease. N Engl J Med. 2023;388(1):9-21. DOI: 10.1056/NEJMoa2212948. PMID: 36449413.
  4. Sims JR, Zimmer JA, Evans CD, et al. Donanemab in Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 2). JAMA. 2023;330(6):512-527. DOI: 10.1001/jama.2023.13239. PMID: 37459141.
  5. Livingston G, Huntley J, Liu KY, et al. Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. Lancet. 2024;404(10452):572-628. DOI: 10.1016/S0140-6736(24)01296-0. PMID: 39096926.
  6. Ngandu T, Lehtisalo J, Solomon A, et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring (FINGER). Lancet. 2015;385(9984):2255-2263. DOI: 10.1016/S0140-6736(15)60461-5. PMID: 25771248.
  7. Hansson O, Edelmayer RM, Boxer AL, et al. The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease. Alzheimers Dement. 2022;18(12):2669-2686. DOI: 10.1002/alz.12756. PMID: 35908803.
  8. Lambert JC, Ibrahim-Verbaas CA, Harold D, et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat Genet. 2013;45(12):1452-1458. DOI: 10.1038/ng.2802. PMID: 24162737.
  9. Katzman R. Editorial: The prevalence and malignancy of Alzheimer disease. Arch Neurol. 1976;33(4):217-218. DOI: 10.1001/archneur.1976.00500040001001. PMID: 1259639.
  10. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups. Alzheimers Dement. 2011;7(3):263-269. DOI: 10.1016/j.jalz.2011.03.005. PMID: 21514250.